Shilpa Medicare, via its wholly-owned subsidiary Shilpa Biologicals, has entered into a three-year definitive agreement with Dr Reddy’s Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing centre at Dharwad, Karnataka. T

The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production. Dr Reddy’s has partnered with HV/RDIF for clinical development of the vaccine and has distribution rights in geographies including India.

Dr Reddy’s will facilitate the transfer of the sputnik technology to Shilpa Biologicals. Under the agreement, Shilpa Biologicals will be responsible for the manufacture of the vaccine, while Dr Reddy’s is responsible for the distribution/marketing of the vaccine in its marketing territories.

The companies are also exploring the option to manufacture Sputnik Light, a single-dose version of the vaccine in the near future.